

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM S-1**  
**REGISTRATION STATEMENT**  
*Under*  
*The Securities Act of 1933*

---

**STOKE THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**2834**  
(Primary Standard Industrial  
Classification Code Number)

**47-1144582**  
(I.R.S. Employer  
Identification Number)

**45 Wiggins Avenue  
Bedford, MA 01730  
(781) 430-8200**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**Edward M. Kaye, M.D.**  
**Chief Executive Officer**  
**Stoke Therapeutics, Inc.**  
**45 Wiggins Avenue**  
**Bedford, MA 01730**  
**(781)-430-8200**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

*Copies to:*

**Effie Toshav, Esq.**  
**Robert A. Freedman, Esq.**  
**Alan Smith, Esq.**  
**Julia Forbess, Esq.**  
**Fenwick & West LLP**  
**555 California Street**  
**San Francisco, California 94104**  
**(415) 875-2300**

**Deanna Kirkpatrick, Esq.**  
**Marcel Fausten, Esq.**  
**Davis Polk & Wardwell LLP**  
**450 Lexington Avenue**  
**New York, NY 10017**  
**(212) 450-4000**

---

**Approximate date of commencement of proposed sale to the public:**  
**As soon as practicable after the effective date of this Registration Statement.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  **333-231700**

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
 Non-accelerated filer  Smaller reporting company   
 Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**CALCULATION OF REGISTRATION FEE**

Title of Each Class of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price Per Share	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee(2)
Common stock, \$0.0001 par value per share	1,369,776	\$18.00	\$24,655,968	\$2,989

- (1) Represents 1,369,776 additional number of shares being registered, including 178,666 additional shares that the underwriters have the option to purchase, if any. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1, as amended (File No. 333-231700).
- (2) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, or the Securities Act, based on the proposed maximum aggregate offering price. The Registrant previously registered securities with an aggregate offering price not to exceed \$123,280,000 on a Registration Statement on Form S-1, as amended (File No. 333-231700), which was declared effective by the Securities and Exchange Commission on June 18, 2019. In accordance with Rule 462(b) under the Securities Act, an additional amount of shares having a proposed maximum aggregate offering price of \$24,655,968 are hereby registered, which includes the additional shares that the underwriters have the option to purchase.

**This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act.**

---

**EXPLANATORY NOTE AND INCORPORATION OF  
CERTAIN INFORMATION BY REFERENCE**

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended (“*Securities Act*”), Stoke Therapeutics, Inc. (“*Registrant*”) is filing this Registration Statement on Form S-1 (this “*Registration Statement*”) with the Securities and Exchange Commission (“*Commission*”). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-1, as amended (File No. 333-231700) (the “*Prior Registration Statement*”), which the Registrant originally filed with the Commission on May 23, 2019, and subsequently amended on June 7, 2019 and June 12, 2019, and which the Commission declared effective on June 18, 2019.

The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate number of shares of common stock offered by the Registrant by 1,369,776 shares, 178,666 of which are subject to purchase upon exercise of the underwriters’ option to purchase additional shares of the Registrant’s common stock. The additional shares that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are incorporated by reference into this Registration Statement.

The required opinions and consents are listed on the Exhibit Index attached hereto and filed herewith.

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
5.1*	<a href="#">Opinion of Fenwick &amp; West LLP</a>
23.1*	<a href="#">Consent of Independent Registered Public Accounting Firm</a>
23.2*	<a href="#">Consent of Fenwick &amp; West LLP (included in Exhibit 5.1)</a>
24.1	<a href="#">Power of Attorney (incorporated by reference to Exhibit 24.1 to the Registration Statement on Form S-1 (Registration No. 333-231700)).</a>

\* Filed herewith

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedford, State of Massachusetts, on the 18<sup>th</sup> day of June 2019.

**STOKE THERAPEUTICS, INC.**

By: /s/ Edward M. Kaye, M.D.

Edward M. Kaye, M.D.

*Chief Executive Officer*

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

<u>Name</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Edward M. Kaye</u> Edward M. Kaye, M.D.	Chief Executive Officer and Director (Principal Executive Officer)	June 18, 2019
<u>/s/ Stephen J. Tulipano</u> Stephen J. Tulipano	Chief Financial Officer (Principal Financial and Accounting Officer)	June 18, 2019
<u>  *</u> Samuel W. Hall, Ph.D.	Director	June 18, 2019
<u>  *</u> Seth L. Harrison, M.D..	Director	June 18, 2019
<u>  *</u> Adrian R. Krainer, Ph.D.	Director	June 18, 2019
<u>  *</u> Arthur A. Levin, Ph.D.	Director	June 18, 2019
<u>  *</u> Arthur O. Tzianabos, Ph.D	Director	June 18, 2019
<u>  *</u> Jennifer C. Burstein	Director	June 18, 2019

\* By Attorney-in-Fact

/s/ Stephen J. Tulipano  
Stephen J. Tulipano



555 CALIFORNIA STREET, 12TH FLOOR SAN FRANCISCO, CA 94104  
TEL 415.875.2300 FAX 415.281.1350 WWW.FENWICK.COM

June 18, 2019

Stoke Therapeutics, Inc.  
45 Wiggins Avenue  
Bedford, MA 01730

Ladies and Gentlemen:

At your request, we have examined the Registration Statement on Form S-1 (the "**Registration Statement**") filed by Stoke Therapeutics, Inc., a Delaware corporation (the "**Company**"), with the Securities and Exchange Commission (the "**Commission**") on June 18, 2019 pursuant to Rule 462(b) of the Securities Act of 1933, as amended (the "**Securities Act**"), in connection with the registration of 1,369,776 shares of the Company's Common Stock (the "**Stock**").

In connection with our opinion expressed below we have examined originals or copies of the underwriting agreement pursuant to which the Stock will be sold to the underwriters, the Registration Statement, the prospectus prepared in connection with the Registration Statement (the "**Prospectus**"), the Company's certificate of incorporation, as amended (the "**Certificate**"), and the Company's bylaws, as amended (the "**Bylaws**"), certain minutes and consents of the Company's board of directors (the "**Board**") or a committee or committees thereof and the Company's stockholders relating to the Registration Statement, the Certificate and the Bylaws, and such other agreements, documents, certificates and statements of the Company, its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. In giving our opinion, we have also relied upon a good standing certificate regarding the Company issued by the Delaware Secretary of State and a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual representations by the Company.

In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as to, the genuineness of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same (other than the Company), the lack of any undisclosed termination, modification, waiver or amendment to any document reviewed by us.

We render this opinion only with respect to, and express no opinion herein concerning the application or effect of the laws of any jurisdiction other than, the existing Delaware General Corporation Law.

In connection with our opinion expressed below, we have assumed that, at or prior to the time of the delivery of any shares of Stock, the Registration Statement will have been declared effective under the Securities Act that the registration will apply to the offer and sale of such shares of Stock and will not have been modified or rescinded and that there will not have occurred any change in law affecting the validity of the issuance of such shares of Stock.

Based upon the foregoing, we are of the opinion that the up to 1,369,776 shares of Stock that may be issued and sold by the Company, when issued, sold and delivered in the manner and for the consideration stated in the Registration Statement and the Prospectus and in accordance with the resolutions adopted by the Board and to be adopted by the Pricing Committee of the Board, will be validly issued, fully paid and nonassessable.

---

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us, if any, in the Registration Statement, the Prospectus constituting a part thereof and any amendments thereto.

This opinion is intended solely for use in connection with issuance and sale of shares of Stock subject to the Registration Statement and is not to be relied upon for any other purpose. This opinion is rendered as of the date first written above and is based solely on our understanding of facts in existence as of such date after the aforementioned examination. In rendering the opinions above, we are opining only as to the specific legal issues expressly set forth therein, and no opinion shall be inferred as to any other matter or matters. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention whether or not such occurrence would affect or modify any of the opinions expressed herein.

Very truly yours,

/s/ Fenwick & West LLP  
**FENWICK & WEST LLP**

---

**Consent of Independent Registered Public Accounting Firm**

The Board of Directors  
Stoke Therapeutics, Inc:

We consent to the use of our report dated March 26, 2019, except as to notes 1 and 14, as to which the date is June 7, 2019, incorporated herein by reference, and to the reference to our firm under heading "Experts" in the prospectus.

/s/ KPMG LLP

Boston, Massachusetts  
June 18, 2019